Cargando…

An Infant Formula with Large, Milk Phospholipid-Coated Lipid Droplets Supports Adequate Growth and Is Well-Tolerated in Healthy, Term Asian Infants: A Randomized, Controlled Double-Blind Clinical Trial

Lipids are essential for healthy infant growth and development. The structural complexity of lipids in human milk is not present in infant milk formula (IF). A concept IF was developed mimicking more closely the structure and composition of human milk fat globules. The current study evaluates whethe...

Descripción completa

Detalles Bibliográficos
Autores principales: Teoh, Oon Hoe, Lin, Tan Pih, Abrahamse-Berkeveld, Marieke, Winokan, Antoinette, Chong, Yap Seng, Yap, Fabian, Marintcheva-Petrova, Maya, van der Beek, Eline M., Shek, Lynette P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8838783/
https://www.ncbi.nlm.nih.gov/pubmed/35276993
http://dx.doi.org/10.3390/nu14030634
_version_ 1784650210241150976
author Teoh, Oon Hoe
Lin, Tan Pih
Abrahamse-Berkeveld, Marieke
Winokan, Antoinette
Chong, Yap Seng
Yap, Fabian
Marintcheva-Petrova, Maya
van der Beek, Eline M.
Shek, Lynette P.
author_facet Teoh, Oon Hoe
Lin, Tan Pih
Abrahamse-Berkeveld, Marieke
Winokan, Antoinette
Chong, Yap Seng
Yap, Fabian
Marintcheva-Petrova, Maya
van der Beek, Eline M.
Shek, Lynette P.
author_sort Teoh, Oon Hoe
collection PubMed
description Lipids are essential for healthy infant growth and development. The structural complexity of lipids in human milk is not present in infant milk formula (IF). A concept IF was developed mimicking more closely the structure and composition of human milk fat globules. The current study evaluates whether a concept IF with large, milk phospholipid-coated lipid droplets (mode diameter 3 to 5 μm) is equivalent to standard IF with regard to growth adequacy and safety in healthy, term Asian infants. In this randomized, double-blind, controlled trial, infants were randomized after parents decided to introduce formula. Infants received a standard IF with (Control) or without the specific prebiotic mixture scGOS/lcFOS (9:1 ratio; Control w/o prebiotics), or a Concept IF with large, milk phospholipid-coated lipid droplets and the prebiotic mixture. A group of 67 breastfed infants served as a reference. As a priori defined, only those infants who were fully intervention formula-fed ≤28 days of age were included in the equivalence analysis (Control n = 29; Control w/o prebiotics n = 28; Concept n = 35, per-protocol population). Primary outcome was daily weight gain during the first four months of life, with the difference between the Concept and Control as the key comparison of interest. Additionally, adverse events, growth and tolerance parameters were evaluated. Equivalence of daily weight gain was demonstrated between the Concept and Control group after additional correction for ethnicity and birthweight (difference in estimated means of 0.1 g/d, 90%CI [−2.30, 2.47]; equivalence margin +/− 3 g/d). No clinically relevant group differences were observed in secondary growth outcomes, tolerance outcomes or number, severity or relatedness of adverse events. This study corroborates that an infant formula with large, milk phospholipid-coated lipid droplets supports adequate growth and is well tolerated and safe for use in healthy infants.
format Online
Article
Text
id pubmed-8838783
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88387832022-02-13 An Infant Formula with Large, Milk Phospholipid-Coated Lipid Droplets Supports Adequate Growth and Is Well-Tolerated in Healthy, Term Asian Infants: A Randomized, Controlled Double-Blind Clinical Trial Teoh, Oon Hoe Lin, Tan Pih Abrahamse-Berkeveld, Marieke Winokan, Antoinette Chong, Yap Seng Yap, Fabian Marintcheva-Petrova, Maya van der Beek, Eline M. Shek, Lynette P. Nutrients Article Lipids are essential for healthy infant growth and development. The structural complexity of lipids in human milk is not present in infant milk formula (IF). A concept IF was developed mimicking more closely the structure and composition of human milk fat globules. The current study evaluates whether a concept IF with large, milk phospholipid-coated lipid droplets (mode diameter 3 to 5 μm) is equivalent to standard IF with regard to growth adequacy and safety in healthy, term Asian infants. In this randomized, double-blind, controlled trial, infants were randomized after parents decided to introduce formula. Infants received a standard IF with (Control) or without the specific prebiotic mixture scGOS/lcFOS (9:1 ratio; Control w/o prebiotics), or a Concept IF with large, milk phospholipid-coated lipid droplets and the prebiotic mixture. A group of 67 breastfed infants served as a reference. As a priori defined, only those infants who were fully intervention formula-fed ≤28 days of age were included in the equivalence analysis (Control n = 29; Control w/o prebiotics n = 28; Concept n = 35, per-protocol population). Primary outcome was daily weight gain during the first four months of life, with the difference between the Concept and Control as the key comparison of interest. Additionally, adverse events, growth and tolerance parameters were evaluated. Equivalence of daily weight gain was demonstrated between the Concept and Control group after additional correction for ethnicity and birthweight (difference in estimated means of 0.1 g/d, 90%CI [−2.30, 2.47]; equivalence margin +/− 3 g/d). No clinically relevant group differences were observed in secondary growth outcomes, tolerance outcomes or number, severity or relatedness of adverse events. This study corroborates that an infant formula with large, milk phospholipid-coated lipid droplets supports adequate growth and is well tolerated and safe for use in healthy infants. MDPI 2022-02-01 /pmc/articles/PMC8838783/ /pubmed/35276993 http://dx.doi.org/10.3390/nu14030634 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Teoh, Oon Hoe
Lin, Tan Pih
Abrahamse-Berkeveld, Marieke
Winokan, Antoinette
Chong, Yap Seng
Yap, Fabian
Marintcheva-Petrova, Maya
van der Beek, Eline M.
Shek, Lynette P.
An Infant Formula with Large, Milk Phospholipid-Coated Lipid Droplets Supports Adequate Growth and Is Well-Tolerated in Healthy, Term Asian Infants: A Randomized, Controlled Double-Blind Clinical Trial
title An Infant Formula with Large, Milk Phospholipid-Coated Lipid Droplets Supports Adequate Growth and Is Well-Tolerated in Healthy, Term Asian Infants: A Randomized, Controlled Double-Blind Clinical Trial
title_full An Infant Formula with Large, Milk Phospholipid-Coated Lipid Droplets Supports Adequate Growth and Is Well-Tolerated in Healthy, Term Asian Infants: A Randomized, Controlled Double-Blind Clinical Trial
title_fullStr An Infant Formula with Large, Milk Phospholipid-Coated Lipid Droplets Supports Adequate Growth and Is Well-Tolerated in Healthy, Term Asian Infants: A Randomized, Controlled Double-Blind Clinical Trial
title_full_unstemmed An Infant Formula with Large, Milk Phospholipid-Coated Lipid Droplets Supports Adequate Growth and Is Well-Tolerated in Healthy, Term Asian Infants: A Randomized, Controlled Double-Blind Clinical Trial
title_short An Infant Formula with Large, Milk Phospholipid-Coated Lipid Droplets Supports Adequate Growth and Is Well-Tolerated in Healthy, Term Asian Infants: A Randomized, Controlled Double-Blind Clinical Trial
title_sort infant formula with large, milk phospholipid-coated lipid droplets supports adequate growth and is well-tolerated in healthy, term asian infants: a randomized, controlled double-blind clinical trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8838783/
https://www.ncbi.nlm.nih.gov/pubmed/35276993
http://dx.doi.org/10.3390/nu14030634
work_keys_str_mv AT teohoonhoe aninfantformulawithlargemilkphospholipidcoatedlipiddropletssupportsadequategrowthandiswelltoleratedinhealthytermasianinfantsarandomizedcontrolleddoubleblindclinicaltrial
AT lintanpih aninfantformulawithlargemilkphospholipidcoatedlipiddropletssupportsadequategrowthandiswelltoleratedinhealthytermasianinfantsarandomizedcontrolleddoubleblindclinicaltrial
AT abrahamseberkeveldmarieke aninfantformulawithlargemilkphospholipidcoatedlipiddropletssupportsadequategrowthandiswelltoleratedinhealthytermasianinfantsarandomizedcontrolleddoubleblindclinicaltrial
AT winokanantoinette aninfantformulawithlargemilkphospholipidcoatedlipiddropletssupportsadequategrowthandiswelltoleratedinhealthytermasianinfantsarandomizedcontrolleddoubleblindclinicaltrial
AT chongyapseng aninfantformulawithlargemilkphospholipidcoatedlipiddropletssupportsadequategrowthandiswelltoleratedinhealthytermasianinfantsarandomizedcontrolleddoubleblindclinicaltrial
AT yapfabian aninfantformulawithlargemilkphospholipidcoatedlipiddropletssupportsadequategrowthandiswelltoleratedinhealthytermasianinfantsarandomizedcontrolleddoubleblindclinicaltrial
AT marintchevapetrovamaya aninfantformulawithlargemilkphospholipidcoatedlipiddropletssupportsadequategrowthandiswelltoleratedinhealthytermasianinfantsarandomizedcontrolleddoubleblindclinicaltrial
AT vanderbeekelinem aninfantformulawithlargemilkphospholipidcoatedlipiddropletssupportsadequategrowthandiswelltoleratedinhealthytermasianinfantsarandomizedcontrolleddoubleblindclinicaltrial
AT sheklynettep aninfantformulawithlargemilkphospholipidcoatedlipiddropletssupportsadequategrowthandiswelltoleratedinhealthytermasianinfantsarandomizedcontrolleddoubleblindclinicaltrial
AT teohoonhoe infantformulawithlargemilkphospholipidcoatedlipiddropletssupportsadequategrowthandiswelltoleratedinhealthytermasianinfantsarandomizedcontrolleddoubleblindclinicaltrial
AT lintanpih infantformulawithlargemilkphospholipidcoatedlipiddropletssupportsadequategrowthandiswelltoleratedinhealthytermasianinfantsarandomizedcontrolleddoubleblindclinicaltrial
AT abrahamseberkeveldmarieke infantformulawithlargemilkphospholipidcoatedlipiddropletssupportsadequategrowthandiswelltoleratedinhealthytermasianinfantsarandomizedcontrolleddoubleblindclinicaltrial
AT winokanantoinette infantformulawithlargemilkphospholipidcoatedlipiddropletssupportsadequategrowthandiswelltoleratedinhealthytermasianinfantsarandomizedcontrolleddoubleblindclinicaltrial
AT chongyapseng infantformulawithlargemilkphospholipidcoatedlipiddropletssupportsadequategrowthandiswelltoleratedinhealthytermasianinfantsarandomizedcontrolleddoubleblindclinicaltrial
AT yapfabian infantformulawithlargemilkphospholipidcoatedlipiddropletssupportsadequategrowthandiswelltoleratedinhealthytermasianinfantsarandomizedcontrolleddoubleblindclinicaltrial
AT marintchevapetrovamaya infantformulawithlargemilkphospholipidcoatedlipiddropletssupportsadequategrowthandiswelltoleratedinhealthytermasianinfantsarandomizedcontrolleddoubleblindclinicaltrial
AT vanderbeekelinem infantformulawithlargemilkphospholipidcoatedlipiddropletssupportsadequategrowthandiswelltoleratedinhealthytermasianinfantsarandomizedcontrolleddoubleblindclinicaltrial
AT sheklynettep infantformulawithlargemilkphospholipidcoatedlipiddropletssupportsadequategrowthandiswelltoleratedinhealthytermasianinfantsarandomizedcontrolleddoubleblindclinicaltrial